KLRK1 and neoplasm: Both in vitro and in vivo phenotype experiments indicated that loss of circARAP2 can alleviate sMICA-induced NK cell desensitization and dysfunction by inhibiting NKG2D endocytosis, thereby enhancing the anti-tumor capacity of NK cells.